Novo Nordisk said its market research shows twice as many US Medicare recipients would rather take a weight-loss pill over a shot, says Executive Vice President of US Operations Jamey Millar
Novo Nordisk said its market research shows twice as many US Medicare recipients would rather take a weight-loss pill over a shot, says Executive Vice President of US Operations Jamey Millar